Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor.

Mutations in TP53 have been reported to be the most frequent oncogenic mutations in non-small-cell lung cancer (NSCLC), but there are no favorable targeted therapies. The association between TP53 mutation and atezolizumab in NSCLC patients was explored in this study. Patients with NSCLC from the POPLAR and OAK studies were included. Longer overall survival (OS) was found in TP53-wildtype NSCLC patients treated with atezolizumab compared with those treated with docetaxel. OS benefit of atezolizumab over docetaxel was detected for NSCLC patients only with co-occurrence of TP53 and KRAS mutations. For patients with NSCLC harboring TP53 mutation detected by fluid biopsy, this study provides insights and perspectives into anti-PD-L1 treatment.